Search

Your search keyword '"Recher, Christian"' showing total 1,350 results
Start Over Author "Recher, Christian"
1,350 results on '"Recher, Christian"'

1. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study

Author

Orvain, Corentin, Bertoli, Sarah, Peterlin, Pierre, Desbrosses, Yohann, Dumas, Pierre-Yves, Iat, Alexandre, Hospital, Marie-Anne, Carre, Martin, Tavernier, Emmanuelle, Riou, Jérémie, Bouvier, Anne, Bidet, Audrey, Tondeur, Sylvie, Renosi, Florian, Mozziconacci, Marie-Joelle, Flandrin-Gresta, Pascale, Dadone-Montaudié, Bérengère, Delabesse, Eric, Pigneux, Arnaud, Hunault-Berger, Mathilde, and Recher, Christian

Published
2024
Full Text
View/download PDF

3. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

Author

Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Recher, Christian, Yoon, Sung-Soo, Maeda, Yoshinobu, Hosono, Naoko, Onozawa, Masahiro, Kato, Takayasu, Kim, Hee-Je, Hasabou, Nahla, Nuthethi, Rishita, Tiu, Ramon, Levis, Mark, Perl, Alexander, Larson, Richard, Podoltsev, Nikolai, Strickland, Stephen, Wang, Eunice, Atallah, Ehab, and Schiller, Gary

Subjects
Acute myelogenous leukemia, FLT3 inhibitor, FLT3 mutation, Hematopoietic stem cell transplantation, Post-transplantation maintenance therapy, Adult, Humans, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Aniline Compounds, Recurrence
Abstract

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. In this study, we assessed survival and relapse rates of patients in the ADMIRAL trial who underwent hematopoietic stem cell transplantation (HSCT), as well as safety outcomes in patients who received post-transplantation gilteritinib maintenance therapy. ADMIRAL was a global phase 3 randomized controlled trial that enrolled adult patients with FLT3-mutated R/R AML. Patients with R/R AML who harbored FLT3 internal tandem duplication mutations in the juxtamembrane domain or D835/I836 point mutations in the tyrosine kinase domain were randomized (2:1) to gilteritinib (120 mg/day) or to preselected high- or low-intensity salvage chemotherapy (1 or 2 cycles). Patients in the gilteritinib arm who proceeded to HSCT could receive post-transplantation gilteritinib maintenance therapy if they were within 30 to 90 days post-transplantation and had achieved composite complete remission (CRc) with successful engraftment and no post-transplantation complications. Adverse events (AEs) during HSCT were recorded in the gilteritinib arm only. Survival outcomes and the cumulative incidence of relapse were assessed in patients who underwent HSCT during the trial. Treatment-emergent AEs were evaluated in patients who restarted gilteritinib as post-transplantation maintenance therapy. Patients in the gilteritinib arm underwent HSCT more frequently than those in the chemotherapy arm (26% [n = 64] versus 15% [n = 19]). For all transplantation recipients, 12- and 24-month overall survival (OS) rates were 68% and 47%, respectively. Despite a trend toward longer OS after pretransplantation CRc, post-transplantation survival was comparable in the 2 arms. Patients who resumed gilteritinib after HSCT had a low relapse rate after pretransplantation CRc (20%) or CR (0%). The most common AEs observed with post-transplantation gilteritinib therapy were increased alanine aminotransferase level (45%), pyrexia (43%), and diarrhea (40%); grade ≥3 AEs were related primarily to myelosuppression. The incidences of grade ≥III acute graft-versus-host disease and related mortality were low. Post-transplantation survival was similar across the 2 study arms in the ADMIRAL trial, but higher remission rates with gilteritinib facilitated receipt of HSCT. Gilteritinib as post-transplantation maintenance therapy had a stable safety and tolerability profile and was associated with low relapse rates. Taken together, these data support a preference for bridging therapy with gilteritinib over chemotherapy in transplantation-eligible patients.

Published
2023

4. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine

Author

Pollyea, Daniel A, Pratz, Keith W, Wei, Andrew H, Pullarkat, Vinod, Jonas, Brian A, Recher, Christian, Babu, Sunil, Schuh, Andre C, Dail, Monique, Sun, Yan, Potluri, Jalaja, Chyla, Brenda, and DiNardo, Courtney D

Subjects
Cancer, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Humans, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Cytogenetic Analysis, Leukemia, Myeloid, Acute, Mutation, Tumor Suppressor Protein p53, Treatment Outcome, Clinical Trials, Phase III as Topic, Clinical Trials, Phase I as Topic, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo evaluate efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with acute myeloid leukemia harboring poor-risk cytogenetics and TP53mut or TP53wt.Patients and methodsWe analyzed data from a phase III study (NCT02993523) comparing venetoclax (400 mg orally days 1-28) + azacitidine (75 mg/m2 days 1-7) or placebo + azacitidine, and from a phase Ib study (NCT02203773) of venetoclax + azacitidine. Patients were ineligible for intensive therapy. TP53 status was analyzed centrally; cytogenetic studies were performed locally.ResultsPatients (n = 127) with poor-risk cytogenetics receiving venetoclax + azacitidine (TP53wt = 50; TP53mut = 54) were compared with patients with poor-risk cytogenetics (n = 56) receiving azacitidine alone (TP53wt = 22; TP53mut = 18).For poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine versus azacitidine alone resulted in composite remission rates (CRc) of 70% versus 23%, median duration of remission (DoR) of 18.4 versus 8.5 months, and median overall survival (OS) of 23.4 versus 11.3 months, respectively. Outcomes with venetoclax + azacitidine were comparable with similarly treated patients with intermediate-risk cytogenetics and TP53wt.For poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine versus azacitidine alone resulted in CRc of 41% versus 17%, median DoR of 6.5 versus 6.7 months, and median OS of 5.2 versus 4.9 months, respectively.For poor-risk cytogenetics + TP53mut patients, predominant grade ≥3 adverse events (AE) for venetoclax + azacitidine versus azacitidine were febrile neutropenia (55%/39%), thrombocytopenia (28%/28%), neutropenia (26%/17%), anemia (13%/6%), and pneumonia (28%/33%). AEs were comparable between TP53mut and TP53wt patients.ConclusionsIn poor-risk cytogenetics + TP53mut patients, venetoclax + azacitidine improved remission rates but not DoR or OS compared with azacitidine alone. However, in poor-risk cytogenetics + TP53wt patients, venetoclax + azacitidine resulted in higher remission rates and longer DoR and OS than azacitidine alone, with outcomes comparable with similarly treated patients with intermediate-risk cytogenetics. Toxicities were similar in TP53mut and TP53wt patients. See related commentary by Green and Zeidner, p. 5235.

Published
2022

6. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia

Author

Le Floch, Anne-Charlotte, Orlanducci, Florence, Béné, Marie-Christine, Ben Amara, Amira, Rouviere, Marie-Sarah, Salem, Nassim, Le Roy, Aude, Cordier, Charlotte, Demerlé, Clémence, Granjeaud, Samuel, Hamel, Jean-François, Ifrah, Norbert, Cornillet-Lefebvre, Pascale, Delaunay, Jacques, Récher, Christian, Delabesse, Eric, Pigneux, Arnaud, Vey, Norbert, Chretien, Anne-Sophie, and Olive, Daniel

Published
2024
Full Text
View/download PDF

7. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Author

Roboz, Gail J., Sanz, Guillermo, Griffiths, Elizabeth A., Yee, Karen, Kantarjian, Hagop, Récher, Christian, Byrne, Michael T., Patkowska, Elżbieta, Kim, Hee-Je, Thomas, Xavier, Moors, Ine, Stock, Wendy, Illés, Árpád, Fenaux, Pierre, Miyazaki, Yasushi, Yamauchi, Takahiro, O'Connell, Casey L., Hao, Yong, Keer, Harold N., Azab, Mohammad, and Döhner, Hartmut

Published
2024
Full Text
View/download PDF

8. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Author

Pratz, Keith W, Jonas, Brian A, Pullarkat, Vinod, Recher, Christian, Schuh, Andre C, Thirman, Michael J, Garcia, Jacqueline S, DiNardo, Courtney D, Vorobyev, Vladimir, Fracchiolla, Nicola S, Yeh, Su-Peng, Jang, Jun Ho, Ozcan, Muhit, Yamamoto, Kazuhito, Illes, Arpad, Zhou, Ying, Dail, Monique, Chyla, Brenda, Potluri, Jalaja, and Döhner, Hartmut

Subjects
Clinical Research, Prevention, Cancer, Hematology, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Myeloid, Acute, Neoplasm, Residual, Prognosis, Remission Induction, Sulfonamides, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThere is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10-3 in the VIALE-A trial.MethodsThe patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10-3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS.ResultsOne hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10-3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10-3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10-3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10-3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10-3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001).ConclusionPatients who achieved CRc and MRD < 10-3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10-3.

Published
2022

9. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

Author

Pratz, Keith W, Panayiotidis, Panayiotis, Recher, Christian, Wei, Xudong, Jonas, Brian A, Montesinos, Pau, Ivanov, Vladimir, Schuh, Andre C, DiNardo, Courtney D, Novak, Jan, Pejsa, Vlatko, Stevens, Don, Yeh, Su-Peng, Kim, Inho, Turgut, Mehmet, Fracchiolla, Nicola, Yamamoto, Kazuhito, Ofran, Yishai, Wei, Andrew H, Bui, Cat N, Benjamin, Katy, Kamalakar, Rajesh, Potluri, Jalaja, Mendes, Wellington, Devine, Jacob, and Fiedler, Walter

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Cancer, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Cytarabine, Fatigue, Humans, Leukemia, Myeloid, Acute, Quality of Life, Sulfonamides, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of ≥10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.

Published
2022

10. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia

Author

Joudinaud, Romane, Boudry, Augustin, Fenwarth, Laurène, Geffroy, Sandrine, Salson, Mikaël, Dombret, Hervé, Berthon, Céline, Pigneux, Arnaud, Lebon, Delphine, Peterlin, Pierre, Bouzy, Simon, Flandrin-Gresta, Pascale, Tavernier, Emmanuelle, Carre, Martin, Tondeur, Sylvie, Haddaoui, Lamya, Itzykson, Raphael, Bertoli, Sarah, Bidet, Audrey, Delabesse, Eric, Hunault, Mathilde, Récher, Christian, Preudhomme, Claude, Duployez, Nicolas, and Dumas, Pierre-Yves

Published
2024
Full Text
View/download PDF

11. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study

Author

Didi, Ibrahim, Alliot, Jean-Marc, Dumas, Pierre-Yves, Vergez, François, Tavitian, Suzanne, Largeaud, Laëtitia, Bidet, Audrey, Rieu, Jean-Baptiste, Luquet, Isabelle, Lechevalier, Nicolas, Delabesse, Eric, Sarry, Audrey, De Grande, Anne-Charlotte, Bérard, Emilie, Pigneux, Arnaud, Récher, Christian, Simoncini, David, and Bertoli, Sarah

Published
2024
Full Text
View/download PDF

13. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Author

Vasseur, Loïc, Fenwarth, Laurène, Lambert, Jérôme, de Botton, Stéphane, Figeac, Martin, Villenet, Céline, Heiblig, Maël, Dumas, Pierre-Yves, Récher, Christian, Berthon, Céline, Lemasle, Emilie, Lebon, Delphine, Lambert, Juliette, Terré, Christine, Celli-Lebras, Karine, Dombret, Hervé, Preudhomme, Claude, Cheok, Meyling, Itzykson, Raphael, and Duployez, Nicolas

Published
2023
Full Text
View/download PDF

14. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Author

Thieblemont, Catherine, Altmann, Bettina, Frontzek, Fabian, Renaud, Loïc, Chartier, Loic, Ketterer, Nicolas, Récher, Christian, Poeschel, Viola, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Morschhauser, Franck, Glass, Bertram, Mounier, Nicolas, Tilly, Herve, Rosenwald, Andreas, Ott, German, Lenz, Georg, Molina, Thierry, Ziepert, Marita, and Schmitz, Norbert

Published
2023
Full Text
View/download PDF

15. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

Author

de Botton, Stéphane, Fenaux, Pierre, Yee, Karen, Récher, Christian, Wei, Andrew H., Montesinos, Pau, Taussig, David C., Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Jonas, Brian A., Khwaja, Asim, Legrand, Ollivier, Peterlin, Pierre, Arnan, Montserrat, Blum, William, Cilloni, Daniela, Hiwase, Devendra K., Jurcic, Joseph G., Krauter, Jürgen, Thomas, Xavier, Watts, Justin M., Yang, Jay, Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Barrett, Emma, and Cortes, Jorge

Published
2023
Full Text
View/download PDF

16. Overlapping features of therapy-related and de novo NPM1-mutated AML

Author

Othman, Jad, Meggendorfer, Manja, Tiacci, Enrico, Thiede, Christian, Schlenk, Richard, Dillon, Richard, Stasik, Sebastian, Venanzi, Alessandra, Bertoli, Sarah, Delabesse, Eric, Dumas, Pierre-Yves, Pigneux, Arnaud, Bidet, Audrey, Gilkes, Amanda F., Thomas, Ian, Voso, Maria Teresa, Rambaldi, Alessandro, Brunetti, Lorenzo, Perriello, Vincenzo M., Andresen, Vibeke, Gjertsen, Bjorn T., Martelli, Maria Paola, Récher, Christian, Röllig, Christoph, Bornhäuser, Martin, Serve, Hubert, Müller-Tidow, Carsten, Baldus, Claudia D., Haferlach, Tortsten, Russell, Nigel, and Falini, Brunangelo

Published
2023
Full Text
View/download PDF

17. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Author

Watts, Justin M, Baer, Maria R, Yang, Jay, Prebet, Thomas, Lee, Sangmin, Schiller, Gary J, Dinner, Shira N, Pigneux, Arnaud, Montesinos, Pau, Wang, Eunice S, Seiter, Karen P, Wei, Andrew H, De Botton, Stephane, Arnan, Montserrat, Donnellan, Will, Schwarer, Anthony P, Récher, Christian, Jonas, Brian A, Ferrell, P Brent, Jr, Marzac, Christophe, Kelly, Patrick, Sweeney, Jennifer, Forsyth, Sanjeev, Guichard, Sylvie M, Brevard, Julie, Henrick, Patrick, Mohamed, Hesham, and Cortes, Jorge E

Published
2023
Full Text
View/download PDF

18. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Author

Duployez, Nicolas, Largeaud, Laëtitia, Duchmann, Matthieu, Kim, Rathana, Rieunier, Julie, Lambert, Juliette, Bidet, Audrey, Larcher, Lise, Lemoine, Jean, Delhommeau, François, Hirsch, Pierre, Fenwarth, Laurène, Kosmider, Olivier, Decroocq, Justine, Bouvier, Anne, Le Bris, Yannick, Ochmann, Marlène, Santagostino, Alberto, Adès, Lionel, Fenaux, Pierre, Thomas, Xavier, Micol, Jean-Baptiste, Gardin, Claude, Itzykson, Raphael, Soulier, Jean, Clappier, Emmanuelle, Recher, Christian, Preudhomme, Claude, Pigneux, Arnaud, Dombret, Hervé, Delabesse, Eric, and Sébert, Marie

Published
2022
Full Text
View/download PDF

19. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Author

Konopleva, Marina Y., Röllig, Christoph, Cavenagh, Jamie, Deeren, Dries, Girshova, Larisa, Krauter, Jürgen, Martinelli, Giovanni, Montesinos, Pau, Schäfer, Jonas A., Ottmann, Oliver, Petrini, Mario, Pigneux, Arnaud, Rambaldi, Alessandro, Recher, Christian, Rodriguez-Veiga, Rebeca, Taussig, David, Vey, Norbert, Yoon, Sung-Soo, Ott, Marion, Muehlbauer, Susanne, Beckermann, Benjamin M., Catalani, Olivier, Genevray, Magali, Mundt, Kirsten, Jamois, Candice, Fenaux, Pierre, and Wei, Andrew H.

Published
2022
Full Text
View/download PDF

20. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia

Author

Decroocq, Justine, Birsen, Rudy, Montersino, Camille, Chaskar, Prasad, Mano, Jordi, Poulain, Laury, Friedrich, Chloe, Alary, Anne-Sophie, Guermouche, Helene, Sahal, Ambrine, Fouquet, Guillemette, Gotanègre, Mathilde, Simonetta, Federico, Mouche, Sarah, Gestraud, Pierre, Lescure, Auriane, Del Nery, Elaine, Bosc, Claudie, Grenier, Adrien, Mazed, Fetta, Mondesir, Johanna, Chapuis, Nicolas, Ho, Liza, Boughalem, Aicha, Lelorc’h, Marc, Gobeaux, Camille, Fontenay, Michaela, Recher, Christian, Vey, Norbert, Guillé, Arnaud, Birnbaum, Daniel, Hermine, Olivier, Radford-Weiss, Isabelle, Tsantoulis, Petros, Collette, Yves, Castellano, Rémy, Sarry, Jean-Emmanuel, Pasmant, Eric, Bouscary, Didier, Kosmider, Olivier, and Tamburini, Jerome

Published
2022
Full Text
View/download PDF

22. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Author

Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, and Levis, Mark J.

Published
2022
Full Text
View/download PDF

24. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study

Author

Devillier, Raynier, Forcade, Edouard, Garnier, Alice, Guenounou, Sarah, Thepot, Sylvian, Guillerm, Gaelle, Ceballos, Patrice, Hicheri, Yosr, Dumas, Pierre-Yves, Peterlin, Pierre, Hunault-Berger, Mathilde, Béné, Marie-Christine, Bouvier, Anne, Chevallier, Patrice, Blaise, Didier, Vey, Norbert, Pigneux, Arnaud, Récher, Christian, and Huynh, Anne

Published
2022
Full Text
View/download PDF

26. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

Author

Lambert, Juliette, Lambert, Jerome, Thomas, Xavier, Marceau-Renaut, Alice, Micol, Jean-Baptiste, Renneville, Aline, Clappier, Emmanuelle, Hayette, Sandrine, Récher, Christian, Raffoux, Emmanuel, Pigneux, Arnaud, Berthon, Celine, Terré, Christine, Celli-Lebras, Karine, Castaigne, Sylvie, Boissel, Nicolas, Rousselot, Philippe, Preudhomme, Claude, Dombret, Hervé, and Duployez, Nicolas

Published
2021
Full Text
View/download PDF

28. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study

Author

Duchmann, Matthieu, Micol, Jean-Baptiste, Duployez, Nicolas, Raffoux, Emmanuel, Thomas, Xavier, Marolleau, Jean-Pierre, Braun, Thorsten, Adès, Lionel, Chantepie, Sylvain, Lemasle, Emilie, Berthon, Céline, Malfuson, Jean-Valère, Pautas, Cécile, Lambert, Juliette, Boissel, Nicolas, Celli-Lebras, Karine, Caillot, Denis, Turlure, Pascal, Vey, Norbert, Pigneux, Arnaud, Recher, Christian, Terré, Christine, Gardin, Claude, Itzykson, Raphaël, Preudhomme, Claude, Dombret, Hervé, and de Botton, Stéphane

Published
2021
Full Text
View/download PDF

29. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Author

Zafrani, Lara, Mariotte, Eric, Lemiale, Virginie, Arnulf, Bertrand, Boissel, Nicolas, Thieblemont, Catherine, Rabian, Florence, Harel, Stéphanie, Di Blasi, Roberta, Delgado, Julio, Ortiz, Valentin, Blaise, Didier, Fürst, Sabine, Legrand, Faezeh, Chabannon, Christian, Forcade, Edouard, Gros, François-Xavier, Borel, Cécile, Huynh, Anne, Récher, Christian, Rudzki, Jakob, Rakszawski, Kevin, Sesques, Pierre, Bachy, Emmanuel, Salles, Gilles, Perales, Miguel A, Wohlfarth, Philipp, Staudingert, Thomas, Jäger, Ulrich, Cartron, Guillaume, Fégueux, Nathalie, Ceballos, Patrice, Platon, Laura, Gastinne, Thomas, Tessoulin, Benoit, Le Bourgeois, Amandine, Gavrilina, Olga, Sureda, Anna, Mussetti, Alberto, Borrega, Jorge Garcia, Borchmann, Peter, Lin, Yi, Benjamin, Reuben, de Guibert, Sophie, Quelven, Quentin, Yakoub-Agha, Ibrahim, Beauvais, David, Rubio, Marie-Therese, Azoulay, Élie, Castro, Pedro, Maamar, Adel, Metaxa, Victoria, de Moraes, Alice Gallo, Voigt, Louis, Wallet, Florent, Klouche, Kada, Picard, Muriel, Moreau, Anne-Sophie, Van De Louw, Andry, Seguin, Amélie, Mokart, Djamel, Chawla, Sanjay, Leroy, Julien, Böll, Boris, Issa, Nahema, Levy, Bruno, Hemelaar, Pleun, Fernandez, Sara, Munshi, Laveena, Bauer, Philippe, Schellongowski, Peter, Joannidis, Michael, Moreno-Gonzalez, Gabriel, Galstian, Gennadii, Darmon, Michael, and Valade, Sandrine

Published
2021
Full Text
View/download PDF

31. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Author

Uy, Geoffrey L., Aldoss, Ibrahim, Foster, Matthew C., Sayre, Peter H., Wieduwilt, Matthew J., Advani, Anjali S., Godwin, John E., Arellano, Martha L., Sweet, Kendra L., Emadi, Ashkan, Ravandi, Farhad, Erba, Harry P., Byrne, Michael, Michaelis, Laura, Topp, Max S., Vey, Norbert, Ciceri, Fabio, Carrabba, Matteo Giovanni, Paolini, Stefania, Huls, Gerwin A., Jongen-Lavrencic, Mojca, Wermke, Martin, Chevallier, Patrice, Gyan, Emmanuel, Récher, Christian, Stiff, Patrick J., Pettit, Kristen M., Löwenberg, Bob, Church, Sarah E., Anderson, Erica, Vadakekolathu, Jayakumar, Santaguida, Marianne, Rettig, Michael P., Muth, John, Curtis, Teia, Fehr, Erin, Guo, Kuo, Zhao, Jian, Bakkacha, Ouiam, Jacobs, Kenneth, Tran, Kathy, Kaminker, Patrick, Kostova, Maya, Bonvini, Ezio, Walter, Roland B., Davidson-Moncada, Jan K., Rutella, Sergio, and DiPersio, John F.

Published
2021
Full Text
View/download PDF

32. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Author

Fenwarth, Laurène, Thomas, Xavier, de Botton, Stéphane, Duployez, Nicolas, Bourhis, Jean-Henri, Lesieur, Auriane, Fortin, Gael, Meslin, Paul-Arthur, Yakoub-Agha, Ibrahim, Sujobert, Pierre, Dumas, Pierre-Yves, Récher, Christian, Lebon, Delphine, Berthon, Céline, Michallet, Mauricette, Pigneux, Arnaud, Nguyen, Stéphanie, Chantepie, Sylvain, Vey, Norbert, Raffoux, Emmanuel, Celli-Lebras, Karine, Gardin, Claude, Lambert, Juliette, Malfuson, Jean-Valère, Caillot, Denis, Maury, Sébastien, Ducourneau, Benoît, Turlure, Pascal, Lemasle, Emilie, Pautas, Cécile, Chevret, Sylvie, Terré, Christine, Boissel, Nicolas, Socié, Gérard, Dombret, Hervé, Preudhomme, Claude, and Itzykson, Raphael

Published
2021
Full Text
View/download PDF

33. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

Author

Chiche, Edmond, Rahmé, Ramy, Bertoli, Sarah, Dumas, Pierre-Yves, Micol, Jean-Baptiste, Hicheri, Yosr, Pasquier, Florence, Peterlin, Pierre, Chevallier, Patrice, Thomas, Xavier, Loschi, Michael, Genthon, Alexis, Legrand, Ollivier, Mohty, Mohamad, Raffoux, Emmanuel, Auberger, Patrick, Caulier, Alexis, Joris, Magalie, Bonmati, Caroline, Roth-Guepin, Gabrielle, Lejeune, Caroline, Pigneux, Arnaud, Vey, Norbert, Recher, Christian, Ades, Lionel, and Cluzeau, Thomas

Published
2021
Full Text
View/download PDF

34. Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models.

Author

Larrue, Clement, Mouche, Sarah, Angelino, Paolo, Sajot, Maxime, Birsen, Rudy, Kosmider, Olivier, Mckee, Thomas, Vergez, François, Recher, Christian, Mas, Véronique Mansat-De, Gu, Qiong, Xu, Jun, Tsantoulis, Petros, Sarry, Jean-Emmanuel, and Tamburini, Jerome

Subjects
ACUTE myeloid leukemia, CANCER stem cells, AUTOPHAGY, PRELEUKEMIA, MYELOID cells, HEMATOLOGIC malignancies, IRON metabolism
Abstract

Acute myeloid leukemia (AML) remains a challenging hematological malignancy with poor prognosis and limited treatment options. Leukemic stem cells (LSCs) contribute to therapeutic failure, relapse, and adverse outcome. This study investigates the role of quiescence and related molecular mechanisms in AML pathogenesis and LSC functions to identify potential therapeutic targets. Transcriptomic analysis revealed that the LSC-enriched quiescent cell population has a distinct gene signature with prognostic relevance in patients with AML. Mechanistically, quiescent blasts exhibit increased autophagic activity, which contributes to their sustained viability. Proteomic profiling uncovered differential requirements for iron metabolism between quiescent and cycling cells, revealing a unique dependence of quiescent cells on ferritinophagy, a selective form of autophagy mediated by nuclear receptor coactivator 4 (NCOA4), which regulates iron bioavailability. We evaluated the therapeutic potential of inhibiting NCOA4-mediated ferritinophagy using genetic knockdown and chemical inhibition approaches. In vitro assays showed that suppression of NCOA4 was toxic to leukemic blasts, particularly the CD34+CD38− LSC-enriched population, without affecting normal CD34+ hematopoietic progenitors. In vivo studies using murine patient-derived xenograft (PDX) models of AML confirmed that NCOA4 inhibition reduced tumor burden and impaired LSC viability and self-renewal, indicating a specific vulnerability of these cells to ferritinophagy disruption. Our findings underscore the role of NCOA4-mediated ferritinophagy in maintaining LSC quiescence and function and suggest that targeting this pathway may be an effective therapeutic strategy for AML. This study highlights the potential of NCOA4 inhibition to improve AML outcomes and paves the way for future research and clinical development. Editor's summary: Leukemia stem cells (LSCs) are thought to be a main contributor to relapse in patients with acute myeloid leukemia (AML). Here, Larrue et al. identified a reliance on ferritinophagy, a form of autophagy that relies on nuclear receptor coactivator 4 (NCOA4), in LSCs and demonstrated that inhibition reduced tumor growth in primary patient samples and mouse models. This represents a promising therapeutic strategy for patients with AML that will require further study. —Dorothy Hallberg [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Author

Perl, Alexander E., Hosono, Naoko, Montesinos, Pau, Podoltsev, Nikolai, Martinelli, Giovanni, Panoskaltsis, Nicki, Recher, Christian, Smith, Catherine C., Levis, Mark J., Strickland, Stephen, Röllig, Christoph, Groß-Langenhoff, Marco, Chou, Wen-Chien, Lee, Je-Hwan, Yokoyama, Hisayuki, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon V., and Altman, Jessica K.

Published
2022
Full Text
View/download PDF

37. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome

Author

Dumas, Pierre-Yves, Bertoli, Sarah, Bérard, Emilie, Leguay, Thibaut, Tavitian, Suzanne, Galtier, Jean, Alric, Camille, Bidet, Audrey, Delabesse, Eric, Rieu, Jean Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, Sarry, Audrey, Rey, Héloïse, de Grande, Anne-Charlotte, Despas, Fabien, Pigneux, Arnaud, and Récher, Christian

Published
2020
Full Text
View/download PDF

39. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Author

Ravandi, Farhad, Ritchie, Ellen K, Sayar, Hamid, Lancet, Jeffrey E, Craig, Michael D, Vey, Norbert, Strickland, Stephen A, Schiller, Gary J, Jabbour, Elias, Erba, Harry P, Pigneux, Arnaud, Horst, Heinz-August, Recher, Christian, Klimek, Virginia M, Cortes, Jorge, Roboz, Gail J, Odenike, Olatoyosi, Thomas, Xavier, Havelange, Violaine, Maertens, Johan, Derigs, Hans-Günter, Heuser, Michael, Damon, Lloyd, Powell, Bayard L, Gaidano, Gianluca, Carella, Angelo-Michele, Wei, Andrew, Hogge, Donna, Craig, Adam R, Fox, Judith A, Ward, Renee, Smith, Jennifer A, Acton, Gary, Mehta, Cyrus, Stuart, Robert K, and Kantarjian, Hagop M

Subjects
Humans, Neoplasm Recurrence, Local, Thiazoles, Naphthyridines, Cytarabine, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Treatment Outcome, Remission Induction, Double-Blind Method, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Leukemia, Myeloid, Acute, Kaplan-Meier Estimate, Clinical Research, Cancer, Clinical Trials and Supportive Activities, Hematology, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundSafe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone derivative, plus cytarabine in patients with relapsed or refractory acute myeloid leukaemia.MethodsThis phase 3, double-blind, placebo-controlled trial was undertaken at 101 international sites. Eligible patients with acute myeloid leukaemia were aged 18 years of age or older and had refractory disease or were in first relapse after one or two cycles of previous induction chemotherapy, including at least one cycle of anthracycline (or anthracenedione) plus cytarabine. Patients were randomly assigned 1:1 to vosaroxin (90 mg/m(2) intravenously on days 1 and 4 in a first cycle; 70 mg/m(2) in subsequent cycles) plus cytarabine (1 g/m(2) intravenously on days 1-5) or placebo plus cytarabine through a central interactive voice system with a permuted block procedure stratified by disease status, age, and geographical location. All participants were masked to treatment assignment. The primary efficacy endpoint was overall survival and the primary safety endpoint was 30-day and 60-day all-cause mortality. Efficacy analyses were done by intention to treat; safety analyses included all treated patients. This study is registered with ClinicalTrials.gov, number NCT01191801.FindingsBetween Dec 17, 2010, and Sept 25, 2013, 711 patients were randomly assigned to vosaroxin plus cytarabine (n=356) or placebo plus cytarabine (n=355). At the final analysis, median overall survival was 7·5 months (95% CI 6·4-8·5) in the vosaroxin plus cytarabine group and 6·1 months (5·2-7·1) in the placebo plus cytarabine group (hazard ratio 0·87, 95% CI 0·73-1·02; unstratified log-rank p=0·061; stratified p=0·024). A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group (107 [30%] of 356 patients vs 58 [16%] of 355 patients, p

Published
2015

40. Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

Author

Cortes, Jorge E, Goldberg, Stuart L, Feldman, Eric J, Rizzeri, David A, Hogge, Donna E, Larson, Melissa, Pigneux, Arnaud, Recher, Christian, Schiller, Gary, Warzocha, Krzysztof, Kantarjian, Hagop, Louie, Arthur C, and Kolitz, Jonathan E

Subjects
Childhood Leukemia, Pediatric, Clinical Trials and Supportive Activities, Clinical Research, Hematology, Pediatric Cancer, Cancer, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aminoglycosides, Amsacrine, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Cladribine, Cytarabine, Daunorubicin, Disease-Free Survival, Etoposide, Female, Gemtuzumab, Humans, Injections, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Liposomes, Male, Middle Aged, Mitoxantrone, Recurrence, Remission Induction, Risk Assessment, Salvage Therapy, Treatment Outcome, Vidarabine, Acute Myeloid Leukemia, Phase II, First Relapse, Chemotherapy Intervention, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundCPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy.MethodsThis phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. Control salvage treatment was usually based on cytarabine and anthracycline, often with 1 or more additional agents. Survival at 1 year was the primary efficacy end point.ResultsPatient characteristics were well balanced between the 2 study arms. Improvements in efficacy outcomes were observed following CPX-351, but did not meet prospectively defined statistical criteria for 1-year survival improvement in the overall population. Subset analyses of the EPI-defined poor-risk strata demonstrated higher response rates (39.3% vs 27.6%) and improvements in event-free survival (HR, 0.63; P = .08) and overall survival (HR, 0.55; P = .02). Also, 60-day mortality was lower in the CPX-351 study arm for poor-risk patients (16.1% vs 24.1%).ConclusionsTaken together, the data suggest possible improved outcomes in CPX-351-treated first relapse AML patients with EPI-defined poor-risk disease.

Published
2015

41. Effective interaction in an unbalanced Fermion mixture

Author

Recher, Christian and Kohler, Heinerich

Subjects
Condensed Matter - Quantum Gases, Condensed Matter - Strongly Correlated Electrons
Abstract

A one dimensional Fermi mixture with delta--interaction is investigated in the limit of extreme imbalance. In particular we consider the cases of only one or two minority Fermions which interact with the Fermi-sea of the majority Fermions. We calculate dispersion relation and polaron mass for the minority Fermions as well as equal time density-density correlators. Within a cluster expansion we derive an expression for the effective interaction potential between minority Fermions. For our calculations we use a reformulation of the exact wave functions, originally obtained by Yang and Gaudin by a nested Bethe ansatz, in terms of determinants.

Published
2013

42. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients

Author

Malard, Florent, Vekhoff, Anne, Lapusan, Simona, Isnard, Francoise, D’incan-Corda, Evelyne, Rey, Jérôme, Saillard, Colombe, Thomas, Xavier, Ducastelle-Lepretre, Sophie, Paubelle, Etienne, Larcher, Marie-Virginie, Rocher, Clément, Recher, Christian, Tavitian, Suzanne, Bertoli, Sarah, Michallet, Anne-Sophie, Gilis, Lila, Peterlin, Pierre, Chevallier, Patrice, Nguyen, Stéphanie, Plantamura, Emilie, Boucinha, Lilia, Gasc, Cyrielle, Michallet, Mauricette, Dore, Joel, Legrand, Ollivier, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

43. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Author

Garnache-Ottou, Francine, Vidal, Chrystelle, Biichlé, Sabeha, Renosi, Florian, Poret, Eve, Pagadoy, Maïder, Desmarets, Maxime, Roggy, Anne, Seilles, Estelle, Soret, Lou, Schillinger, Françoise, Puyraimond, Sandrine, Petrella, Tony, Preudhomme, Claude, Roumier, Christophe, MacIntyre, Elisabeth A., Harrivel, Véronique, Desbrosses, Yohan, Gruson, Bérengère, Geneviève, Franck, Thepot, Sylvain, Drebit, Yuriy, Leguay, Thibaut, Gros, François-Xavier, Lechevalier, Nicolas, Saussoy, Pascale, Salaun, Véronique, Cornet, Edouard, Benseddik, Zehaira, Veyrat-Masson, Richard, Wagner-Ballon, Orianne, Salanoubat, Célia, Maynadié, Marc, Guy, Julien, Caillot, Denis, Jacob, Marie-Christine, Cahn, Jean-Yves, Gressin, Rémy, Rose, Johann, Quesnel, Bruno, Guerin, Estelle, Trimoreau, Franck, Feuillard, Jean, Gourin, Marie-Pierre, Plesa, Adriana, Baseggio, Lucile, Arnoux, Isabelle, Vey, Norbert, Blaise, Didier, Lacroix, Romaric, Arnoulet, Christine, Benet, Blandine, Dorvaux, Véronique, Bret, Caroline, Drenou, Bernard, Debliquis, Agathe, Latger-Cannard, Véronique, Bonmati, Caroline, Bene, Marie-Christine, Peterlin, Pierre, Ticchioni, Michel, Rohrlich, Pierre-Simon, Arnaud, Anne, Wickenhauser, Stefan, Bardet, Valérie, Brechignac, Sabine, Papoular, Benjamin, Raggueneau, Victoria, Vargaftig, Jacques, Letestu, Rémi, Lusina, Daniel, Braun, Thorsten, Foissaud, Vincent, Tamburini, Jérôme, Bennani, Hind, Freynet, Nicolas, Cordonnier, Catherine, Le Garff-Tavernier, Magali, Jacques, Nathalie, Maloum, Karim, Roos-Weil, Damien, Bouscary, Didier, Asnafi, Vahid, Lhermitte, Ludovic, Suarez, Felipe, Lengline, Etienne, Féger, Frédéric, Battipaglia, Giorgia, Mohty, Mohamad, Bouyer, Sabrina, Ghoual, Ouda, Dindinaud, Elodie, Basle, Caroline, Puyade, Mathieu, Lafon, Carinne, Fest, Thierry, Roussel, Mikael, Cahu, Xavier, Bera, Elsa, Daliphard, Sylvie, Jardin, Fabrice, Campos, Lydia, Solly, Françoise, Guyotat, Denis, Galoisy, Anne-Cécile, Eischen, Alice, Mayeur-Rousse, Caroline, Guffroy, Blandine, Recher, Christian, Loosveld, Marie, Garnier, Alice, Barlogis, Vincent, Rosenthal, Maria Alessandra, Brun, Sophie, Contentin, Nathalie, Maury, Sébastien, Callanan, Mary, Lefebvre, Christine, Maillard, Natacha, Okamba, Patricia, Ferrand, Christophe, Adotevi, Olivier, Saas, Philippe, Angelot-Delettre, Fanny, Binda, Delphine, and Deconinck, Eric

Published
2019
Full Text
View/download PDF

45. Fidelity and level correlations in the transition from regularity to chaos

Author

Kohler, Heiner and Recher, Christian

Subjects
Quantum Physics, Nonlinear Sciences - Chaotic Dynamics
Abstract

Mean fidelity amplitude and parametric energy--energy correlations are calculated exactly for a regular system, which is subject to a chaotic random perturbation. It turns out that in this particular case under the average both quantities are identical. The result is compared with the susceptibility of chaotic systems against random perturbations. Regular systems are more susceptible against random perturbations than chaotic ones., Comment: 7 pages, 1 figure

Published
2012
Full Text
View/download PDF

46. From hardcore Bosons to free Fermions with Painlev{\'e} V

Author

Recher, Christian and Kohler, Heiner

Subjects
Nonlinear Sciences - Exactly Solvable and Integrable Systems, Condensed Matter - Strongly Correlated Electrons
Abstract

We calculate zero temperature Green's function, the density--density correlation and expectation values of a one--dimensional quantum particle which interacts with a Fermi--sea via a $\delta$--potential. The eigenfunctions of the Bethe-Ansatz solvable model can be expressed as a determinant. This allows us to obtain a compact expression for the Green's function of the extra particle. In the hardcore limit the resulting expression can be analysed further using Painlev{\'e} V transcendents. It is found that depending on the extra particles momentum its Green's function undergoes a transition of that for hardcore Bosons to that of free Fermions., Comment: 27 pages, 7 figures, published version

Published
2011
Full Text
View/download PDF

47. Supersymmetry approach to Wishart correlation matrices: Exact results

Author

Recher, Christian, Kieburg, Mario, Guhr, Thomas, and Zirnbauer, Martin R.

Subjects
Mathematics - Statistics Theory, Mathematical Physics
Abstract

We calculate the `one-point function', meaning the marginal probability density function for any single eigenvalue, of real and complex Wishart correlation matrices. No explicit expression had been obtained for the real case so far. We succeed in doing so by using supersymmetry techniques to express the one-point function of real Wishart correlation matrices as a twofold integral. The result can be viewed as a resummation of a series of Jack polynomials in a non-trivial case. We illustrate our formula by numerical simulations. We also rederive a known expression for the one-point function of complex Wishart correlation matrices., Comment: 21 pages, 2 figures

Published
2010
Full Text
View/download PDF

48. On the Eigenvalue Density of Real and Complex Wishart Correlation Matrices

Author

Recher, Christian, Kieburg, Mario, and Guhr, Thomas

Subjects
Mathematical Physics, Mathematics - Statistics Theory
Abstract

Wishart correlation matrices are the standard model for the statistical analysis of time series. The ensemble averaged eigenvalue density is of considerable practical and theoretical interest. For complex time series and correlation matrices, the eigenvalue density is known exactly. In the real case, however, a fundamental mathematical obstacle made it forbidingly complicated to obtain exact results. We use the supersymmetry method to fully circumvent this problem. We present an exact formula for the eigenvalue density in the real case in terms of twofold integrals and finite sums., Comment: 4 pages, 2 figures

Published
2010
Full Text
View/download PDF

49. Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Author

Da Rocha, Audrey, primary, Cassinat, Bruno, additional, Heiblig, Mael, additional, Recher, Christian, additional, Bertoli, Sarah, additional, Bonmati, Caroline, additional, Roth-Guepin, Gabrielle, additional, Zilliox, Anne, additional, Laloi, Marie, additional, Hunault, Mathilde, additional, Berthon, Céline, additional, Duployez, Nicolas, additional, Willekens, Christophe, additional, Gallego Hernanz, Maria Pilar, additional, Ochmann, Marlene, additional, Cluzeau, Thomas, additional, Chermat, Fatiha, additional, Caulier, Alexis, additional, Raffoux, Emmanuel, additional, Fenaux, Pierre, additional, Marolleau, Jean Pierre, additional, Ades, Lionel, additional, and Lebon, Delphine, additional

Published
2023
Full Text
View/download PDF

50. Clonal Dynamics of FLT3-ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Author

Joudinaud, Romane, primary, Boudry, Augustin, additional, Fenwarth, Laurène, additional, Geffroy, Sandrine, additional, Salson, Mikaël, additional, Dombret, Herve, additional, Berthon, Céline, additional, Pigneux, Arnaud, additional, Lebon, Delphine, additional, Haddaoui, Lamya, additional, Itzykson, Raphael, additional, Recher, Christian, additional, Bidet, Audrey, additional, Delabesse, Eric, additional, Hunault, Mathilde, additional, Preudhomme, Claude, additional, Duployez, Nicolas, additional, and Dumas, Pierre-Yves, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results